Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
|
|
- Berniece Kelly
- 5 years ago
- Views:
Transcription
1 Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
2 Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against the Host tissues
3 Three Requirements for The Development of GVHD 1. Graft must contain immunologically competent cells (T cells) 2. Recipient must express tissue antigens not present in the donor (Antigenic differences) 3. Recipient incapable of mounting an effective response to reject transplanted cells Setting: AlloSCT, transfusion-associated GVHD Billingham
4 GVHD After disease relapse, GVHD is the most common cause of treatment failure after allosct 2 syndromes Acute GVHD (agvhd) Chronic GVHD (cgvhd) Previously defined by temporal relationship to time of transplantation (before and after 100 days) Now defined by clinical features Differences in pathophysiology
5 GVHD After AlloSCT Acute GVHD: Skin, GI, liver Alloreactivity Autoimmunity Immunodeficiency Classic acute Late acute Overlap Chronic GVHD: Skin, eyes, mouth, GI, liver, musculoskeletal, lungs, GU, etc. Classic chronic Day yr 2 yrs 3 yrs 5 yrs Activity (inflammation) Injury Repair Damage (fibrosis)
6 Graft-versus-Leukemia (GVL) Horowitz et al. Blood 1990
7 Horowitz et al. Blood 1990
8 Pathophysiology of agvhd Skin GI Tract Liver Prof. Ferrara T reg T reg
9 Pathophysiology of agvhd N Engl J Med 2017;377:
10 Acute GVHD (agvhd) Incidence: 35% after related donor transplantation 50% after unrelated donor transplantation Despite prophylaxis Current standard prophylaxis: Cyclosporine + MTX better than Cyclosporine alone No benefit in adding corticosteroid Tacrolimus + MTX may be better than cyclosporine + MTX (in unrelated transplant)
11 Classic Approaches to Immunosuppression
12 GVHD Prophylaxis REGIMENS Calcineurin inhibitor (Tacrolimus/Cyclosporine) + MTX Tacrolimus + Sirolimus Cellcept-based regimen ATG-based regimen Decrease both agvhd and cgvhd Post-transplant Cyclophosphamide In haploidentical SCT Continue calcineurin inhibitor for at least 3-6 months and taper Depends on Donor source Risk of disease relapse Occurrence of GVHD
13 Post-transplant Cyclophosphamide Luznik et al. Semin Oncol. 2012
14 Factors Donor-Recipient Factors Major HLA Disparity (HLA Class I,II) Minor HLA Disparity (mha) Sex Matching Donor Parity Donor Age ABO type Donor CMV Serostatus Cytokine Gene Polymorphisms Stem Cell Graft Factors Stem cell source Graft composition Transplantation Factors Conditioning Intensity Increase Risk of agvhd HLA mismatched donor > Matched donor Unrelated donor > Related donor Female donor to male recipient Multiparity > Nulliparity Older donor > Younger donor ABO mismatch > ABO match CMV positive > CMV negative Numerous associated with agvhd PBSC > BM > UCB Higher CD34+ count > Lower CD34+ count Higher T cell dose > Lower T cell dose Myeloablative > RIC regimens
15 Skin GVHD Most commonly affected organ in agvhd 75% of all GVHD patients have some skin involvement 45% have isolated skin involvement Maculopapular rash (typically palms and soles) MP rash -> Bullae -> Desquamation Median time of onset ~ 17 days Main diagnostic consideration: Drug eruption
16 GI GVHD Up to 50% of GVHD patients have GI involvement Upper GI: Nausea/vomiting, anorexia, weight loss Lower GI: Secretory diarrhea (may be bloody), abdominal pain, ileus Often develops during conditioning-related injury period main DDx; also must exclude infection, drug: Endoscopy and biopsy
17 Liver GVHD Least commonly affected organ < 20% Cholestatic jaundice +/- transaminitis as clinical features Drug reaction, TPN, infection, VOD as main alternate diagnostic criteria Biopsy standard for diagnosis (may be difficult due to concurrent thrombocytopenia)
18 Stage Skin BSA (%) agvhd: Staging Liver Bilirubin (mg/dl) Upper GI 1 MP rash <25% 2-3 Persistent N/V or anorexia Lower GI Stool output/day >500 ml % >1000 ml 3 >50% >1500 ml 4 Erythroderma >15 Pain++ + bullae, +/- ileus, desquamation bloody stool The European Group for Blood and Marrow Transplantation
19 agvhd: Consensus Grading Grade Skin Liver GI Stage Stage Stage I II year survival - Grade III: 25% - Grade IV: 5% III IV The European Group for Blood and Marrow Transplantation
20 Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC)
21 31% 5%
22 14% 5%
23 agvhd Treatment Steroid remains the standard first line therapy Methylprednisolone or prednisolone 1-2 mg/kg/day 1mg/kg might be enough for grade II disease CR rate ~ 50% Grade I skin GVHD Managed with topical treatment (0.1% TA or 0.03%/0.1% Tacrolimus cream) + optimizing immunosuppression levels Non-absorbable steroid are very useful adjuvant therapy in GI GVHD Survival correlates directly with the response to initial therapy
24 Advanced agvhd Long term outcome for early agvhd > 80% Much poorer for advanced: Some estimates as low as 10-20% Current 2 nd line agents effective, but too immunosuppressive->infectious death Steroid-refractory GVHD: Defined variably as: Progression after 3 days No response after 7 days Long-term survival 5-30%
25 Salvage Therapy for Steroid-refractory agvhd m-tor inhibitor Sirolimus (Rapamycin) Cellcept Anti-TNF antibodies Infliximab, Etanercept Extracorporeal photopheresis (ECP) T-reg (Regulatory T cells) Mesenchymal stromal cells Fecal microbiota transplantation
26 JAK1/2 Inhibitor in Steroid-refractory agvhd Ruxolitinib -ORR 82% (45/54 pts); CR 46% (25 pts) - Adverse events included cytopenias (56%) and CMV reactivation (33%) Zeiser R, et al. Leukemia. 2015;29:
27 agvhd Biomarkers Markers of inflammation (such as IL-2Rα, TNFR1, ST2) Products secreted when end organs are damaged (such as elafin [skin], REG3α [GI]) ST2, REG3α levels Predict the risk of agvhd Predict treatment response
28 CHULA HSCT Team
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationObjectives. Hematopoietic Stem Cell Transplant. Approaches to Transplant. Indications for HSCT. Define HSCT. Provide overview of HSCT process
Objectives Hematopoietic Stem Cell Transplant Karen Anderson, MN, RN, OCN University of Washington Medical Center Define HSCT Provide overview of HSCT process Discuss acute complications of HSCT Discuss
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationKavita Raj Consultant Haematologist KHP
Kavita Raj Consultant Haematologist KHP 1950s Billingham and Brent injection of spleen cells from adult mice into newborn mice Thickening and loss elasticity of skin, red soles, exfoliation, diarrhoea
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationClinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
Clinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation Reference: NHS England F01X08/01 1 Information Reader Box (IRB)
More informationTreatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota
Treatment of Chronic Graft versus Host Disease Daniel Weisdorf MD University of Minnesota October 2013 Infections Transplant Events d-8 0 1mo 3mo 6mo Conditioning Transplant Engraftment Mucositis Organ
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationWhat is Graft Vs Host Disease?
Graft Failure Graft Versus Host Disease Graft Versus Leukemia Objectives Define graft failure Describe Graft vs. Leukemia effect Review pathophysiology and risk factors for Graft vs. Host Disease (GVHD)
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationAcute GVHD. ESH-EBMT 2009 Latimer A. Devergie
Acute GVHD ESH-EBMT 2009 Latimer A. Devergie Acute GVHD Activated Donor T cells damage host epithelial cells after an inflammatory cascade that begins after the preparative regimen GVHD is the major barrier
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationTransplantation Immunology
Transplantation Immunology Mitchell S. Cairo, MD Professor of Pediatrics, Medicine and Pathology Chief, Division, Pediatric Hematology & Blood & Marrow Transplantation Children s Hospital New York Presbyterian
More informationTransplantation Immunology
Transplantation Immunology MHC Restricted Allograft Rejection Mitchell S. Cairo, MD Professor of Pediatrics, Medicine and Pathology Chief, Division, Pediatric Hematology & Blood & Marrow Transplantation
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationNon-infectious hepatic complications in patients with GVHD
Non-infectious hepatic complications in patients with GVHD Tapani Ruutu Helsinki University Central Hospital Liver dysfunction in allogeneic stem cell transplantation injury secondary to the cytoreductive
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationAcute Graft versus Host Disease J Apperley 18th ESH-EBMT Training Course Vienna May The European Group for Blood and Marrow Transplantation
Acute Graft versus Host Disease J Apperley 18th ESH-EBMT Training Course Vienna May 8-10 2014 Definition Incidence Pathophysiology Diagnosis Clinical Pathological Acute GvHD Prevention & treatment Pharmacological
More information4/28/2016. Disclosure. Management of Pediatric Hematopoietic Stem-Cell Transplant Complications. Objectives - Technician. Objectives - Pharmacist
Disclosure Management of Pediatric Hematopoietic Stem-Cell Transplant Complications Jenna Bender has no actual or potential conflicts of interest to report Off-label use of medication will be discussed
More informationAlloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche
Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Massimo Fabrizio Martelli Ematologia ed Immunologia Clinica Università degli Studi di Perugia 41 Congresso Nazionale
More informationWhat is Graft Vs Host Disease?
Acute Graft Versus Host Disease Objectives Review pathophysiology of Acute Graft vs. Host Disease (agvhd) Identify Risk factors for agvhd Alison Thomsen RN, CPON Clinical Educator Inpatient Cancer Care
More informationWhere in the TED Does HCT Stuff Go?
Where in the TED Does HCT Stuff Go? Diane J. Knutson TED07_1.ppt Key Concepts What is an HSCT? Why perform one? Who can benefit? Mechanics of transplant Early and Late complications Where on new TED? TED07_2.ppt
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationSamples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationLung Injury after HCT
Lung Injury after HCT J. Douglas Rizzo, MD, MS Financial Disclosure None SCS06_1.ppt Background HCT an important therapeutic modality for malignant and non-malignant diseases Pulmonary Toxicity common
More informationExperience of patients transplanted with naïve T cell depleted stem cell graft in CMUH
Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Tzu-Ting Chen, Wen-Jyi Lo, Chiao-Lin Lin, Ching-Chan Lin, Li-Yuan Bai, Supeng Yeh, Chang-Fang Chiu Hematology and
More informationAre we making progress in GVHD prophylaxis and treatment?
HEMATOPOIETIC STEM CELL TRANSPLANTATION II: TOWARD SAFER ALLOGENEIC TRANSPLANTATION Are we making progress in GVHD prophylaxis and treatment? Steven Z. Pavletic 1 and Daniel H. Fowler 1 1 Center for Cancer
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationClassic and Overlap Chronic Graft-versus-Host Disease (cgvhd) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP)
Classic and Overlap Chronic Graft-versus-Host Disease (cgvhd) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP) Madan H. Jagasia, 1 Bipin N. Savani, 1,2 George Stricklin, 3 Brian
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationBlood and Marrow Transplant Patient Information Sheet
Blood and Marrow Transplant Patient Information Sheet Patient Name MR# DOB Diagnosis Wt. (kg) Ht. (cm) M2 Ethnicity: Sex: UPN # 0.00 BMT Attending: Name Allergies: BMT Coordinator: Name Donor Information:
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationA Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease
A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, 2 Rima Saliba, 1 Marcos de Lima, 1 Sergio Giralt, 1 Borje Andersson,
More information(Chronic) Graft Versus Host Disease: When the transplant is just the beginning of the journey
(Chronic) Graft Versus Host Disease: When the transplant is just the beginning of the journey Kitsada Wudhikarn, MD Division of Hematology, Department of Medicine King Chulalongkorn Memorial Hospital Disclosure
More informationRelated haploidentical donors versus matched unrelated donors
Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationEarly Organ Toxicity Post HCT. Wael Saber, MD, MS
Early Organ Toxicity Post HCT Wael Saber, MD, MS 100-Day Mortality by Year of HCT 100 90 80 70 60 50 40 30 Overall Treatment Related 20 10 0 Introduction Hepatic Veno-Occlusive Disease (VOD), Transplant-Associated
More informationFK506 AND MINI METHOTREXATE FOR THE PREVENTION OF GRAFT-VERSUS- HOST DISEASE IN PEDIATRIC UMBILICAL CORD BLOOD TRANSPLANTATION
FK506 AND MINI METHOTREXATE FOR THE PREVENTION OF GRAFT-VERSUS- HOST DISEASE IN PEDIATRIC UMBILICAL CORD BLOOD TRANSPLANTATION By SUSAN STABA KELLY A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationImmunosuppressive therapy for graft-versus-host disease. Mohamad Mohty Institut Paoli-Calmettes, Marseille
Immunosuppressive therapy for graft-versus-host disease Mohamad Mohty Institut Paoli-Calmettes, Marseille Survival according to GVHD grade (Joint SFGM-TC, DFCI and IBMTR data; N=607) Cahn et al., Blood
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationHigh dose cyclophosphamide in HLAhaploidentical
High dose cyclophosphamide in HLAhaploidentical stem cell transplantation Ephraim J. Fuchs, M.D., M.B.A. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins fuchsep@jhmi.edu Alternative Donor Transplantation:
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationTrapianto allogenico
POST ASH 2013: 3 Workshop Regionale Marchigiano 28 Febbraio - 1 Marzo 2014 Hotel Domus Stella Maris, ANCONA REPORT OF THE BEST ASH NEWS Trapianto allogenico Dr. Claudio Giardini U.O. Ematologia e Centro
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More information21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com
Transplant Webinar Series: Ep. 6 Donor Selection for Haematopoietic Stem Cell Transplantation Future Webinars The Role of NGS in the Transplant Setting Featuring Dr Sujatha Krishnakumar Sirona Genomics,
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationSupportive Care in Patients undergoing Haematopoietic Stem Cell Transplant (HSCT)
Supportive Care in Patients undergoing Haematopoietic Stem Cell Transplant (HSCT) Dr. Karim Ibrahim Senior Haematology and BMT Pharmacist St Vincent s Hospital, Sydney 1 Objectives Discuss strategies for
More informationNothing to disclose. Title of the presentation - Author
Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationFactors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection
Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationKD : A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cgvhd) - Pharmacodynamics and Updated Results
KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cgvhd) - Pharmacodynamics and Updated Results Madan Jagasia 1, Amandeep Salhotra 2, Carlos R. Bachier 3, James
More informationRole of clinical laboratory markers of inflammation in assessing chronic graft versus host disease activity and severity
UNIVERSITY OF ZAGREB SCHOOL OF MEDICINE Lana Desnica Role of clinical laboratory markers of inflammation in assessing chronic graft versus host disease activity and severity DISSERTATION Zagreb, 2016 UNIVERSITY
More informationTransplant Booklet D Page 1
Booklet D Pretest Correct Answers 4. (A) is correct. Technically, performing a hematopoietic stem cell transplant is one of the simplest transplantation procedures. The hematopoietic stem cells are infused
More informationCOI disclosure. The International Congress of BMT Name of author : Byong Sik Cho. I have no personal or financial interests to declare:
The International Congress of BMT 2017 COI disclosure Name of author : Byong Sik Cho I have no personal or financial interests to declare: I have no financial support from an industry source at the current
More information11/20/2015. Post Transplant. Problems and limitations of SCT. Bone Marrow Transplant for SAA: Managing Post BMT Health and Support.
Transplant 11/20/2015 Bone Marrow Transplant for SAA: Managing Post BMT Health and Support Richard W. Childs, M.D. Clinical Director NHLBI Chief, Laboratory of Transplantation Immunotherapy Senior Investigator,
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationGVHD: new therapeutic approach. Gyd. A. Bukauskas Hematologijos, onkologijos ir transfuziologijos centras VUH Santariskiu Klinikos
GVHD: new therapeutic approach Gyd. A. Bukauskas Hematologijos, onkologijos ir transfuziologijos centras VUH Santariskiu Klinikos Vedolizumab Vedolizumab (Entyvio) monoclonal antibody for the treatment
More informationOutline. Introduction. Introduction. Introduction. Introduction 27/03/61. Hematologic Stem Cell Transplantation (HSCT)
Outline Hematologic Stem Cell Transplantation (HSCT) Trai Tharnpanich B.Pharm, BCOP, BCP Faculty of medicine, Mahidol university Department of pharmacy, Siriraj hospital 1 Introduction Sources of HSCT
More informationPhotopheresis in Acute Graft-versus- Host Disease Hildegard T. Greinix Medical University of Vienna Austria
Photopheresis in Acute Graft-versus- Host Disease Hildegard T. Greinix Medical University of Vienna Austria Univ. Klinik für Innere Medizin I Acute GvHD is Serious Complication of Allo HCT Challenge: GvL
More informationTransplantation Immunology Booklet C
Booklet C Pretest Correct Answers 3. (C) is correct. One of the major barriers to successful hematopoietic stem cell transplantation is the antigens coded for by the major histocompatibility gene complex.
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationG. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728
G. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728 16:00-17:30 Session 7 GvHD Prevention by T-Cell Modulation Is photopheresis treatment
More informationThe role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationVirological Surveillance in Paediatric HSCT Recipients
Virological Surveillance in Paediatric HSCT Recipients Dr Pamela Lee Clinical Assistant Professor Department of Paediatrics & Adolescent Medicine Queen Mary Hospital LKS Faculty of Medicine, The University
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More information